| 1 | 11106230 | Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. | Clin Cancer Res | 2000 Nov |
4 |
| 2 | 11212278 | In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. | Cancer Res | 2001 Jan 15 |
2 |
| 3 | 12576431 | Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. | Clin Cancer Res | 2003 Feb |
2 |
| 4 | 12712010 | Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. | Cancer Control | 2003 Mar-Apr |
1 |
| 5 | 14534356 | Pumping of drugs by P-glycoprotein: a two-step process? | J Pharmacol Exp Ther | 2003 Dec |
3 |
| 6 | 14962729 | Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. | Eur J Cancer | 2004 Mar |
1 |
| 7 | 14973080 | Pheophorbide a is a specific probe for ABCG2 function and inhibition. | Cancer Res | 2004 Feb 15 |
2 |
| 8 | 15457126 | Ex vivo reversal of chemoresistance by tariquidar (XR9576). | Anticancer Drugs | 2004 Oct |
3 |
| 9 | 15986399 | Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. | Cancer | 2005 Aug 15 |
5 |
| 10 | 16043202 | P-glycoprotein activity and biological response. | Toxicol Appl Pharmacol | 2005 Sep 1 |
1 |
| 11 | 16190932 | A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. | Epilepsia | 2005 Oct |
1 |
| 12 | 16650133 | Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. | Epilepsia | 2006 Apr |
1 |
| 13 | 16928449 | The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy. | Neurobiol Dis | 2006 Oct |
1 |
| 14 | 16952161 | Quantification of serotonin 5-HT1A receptors in monkey brain with [11C](R)-(-)-RWAY. | Synapse | 2006 Dec 1 |
1 |
| 15 | 17027274 | Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development. | Neurobiol Dis | 2006 Dec |
1 |
| 16 | 17326793 | Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. | Epilepsia | 2007 Mar |
2 |
| 17 | 17392402 | Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. | J Pharmacol Exp Ther | 2007 Jul |
1 |
| 18 | 17399990 | In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2). | Bioorg Med Chem | 2007 Jun 1 |
2 |
| 19 | 17428165 | Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. | Expert Rev Anticancer Ther | 2007 Apr |
5 |
| 20 | 17437408 | Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. | Epilepsia | 2007 Apr |
2 |
| 21 | 17881135 | Multidrug-resistance gene 1-type p-glycoprotein (MDR1 p-gp) inhibition by tariquidar impacts on neuroendocrine and behavioral processing of stress. | Psychoneuroendocrinology | 2007 Sep-Nov |
2 |
| 22 | 17936633 | Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. | Bioorg Med Chem | 2008 Jan 1 |
1 |
| 23 | 17958337 | Transport of a new erectogenic udenafil in Caco-2 cells. | Arch Pharm Res | 2007 Sep |
1 |
| 24 | 18632828 | Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. | J Nucl Med | 2008 Aug |
2 |
| 25 | 18664392 | Functional and energetic characterization of P-gp-mediated doxorubicin transport in rainbow trout (Oncorhynchus mykiss) hepatocytes. | Comp Biochem Physiol C Toxicol Pharmacol | 2009 Jan |
4 |
| 26 | 18678495 | Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). | Bioorg Med Chem | 2008 Sep 1 |
2 |
| 27 | 18760905 | Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. | Epilepsy Res | 2008 Nov |
1 |
| 28 | 18824002 | Several major antiepileptic drugs are substrates for human P-glycoprotein. | Neuropharmacology | 2008 Dec |
1 |
| 29 | 19250834 | Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators. | Bioorg Med Chem | 2009 Mar 15 |
1 |
| 30 | 19331851 | Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. | J Control Release | 2009 May 21 |
1 |
| 31 | 19417029 | A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. | Clin Cancer Res | 2009 May 15 |
6 |
| 32 | 19631619 | Polarized P-glycoprotein expression by the immortalised human brain endothelial cell line, hCMEC/D3, restricts apical-to-basolateral permeability to rhodamine 123. | Brain Res | 2009 Oct 6 |
3 |
| 33 | 19654309 | Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. | Cancer Res | 2009 Aug 15 |
1 |
| 34 | 19730994 | The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. | Pharm Res | 2009 Nov |
2 |
| 35 | 19796699 | Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. | Neuroimage | 2010 Jan 15 |
6 |
| 36 | 19910428 | A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. | J Nucl Med | 2009 Dec |
4 |
| 37 | 20010957 | Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. | J Cereb Blood Flow Metab | 2010 Mar |
2 |
| 38 | 20016890 | Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. | Eur J Nucl Med Mol Imaging | 2010 May |
1 |
| 39 | 20181488 | Synthesis of carbon-11-labeled tariquidar derivatives as new PET agents for imaging of breast cancer resistance protein (ABCG2). | Appl Radiat Isot | 2010 Jun |
3 |
| 40 | 20237038 | P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. | J Nucl Med | 2010 Apr |
1 |
| 41 | 20460505 | The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. | Cancer Res | 2010 Jun 1 |
5 |
| 42 | 20610168 | Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate. | Nucl Med Biol | 2010 Jul |
3 |
| 43 | 20621487 | Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. | Bioorg Med Chem | 2010 Aug 1 |
2 |
| 44 | 20633036 | Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. | Epilepsia | 2010 Sep |
1 |
| 45 | 21081657 | A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. | Clin Cancer Res | 2011 Feb 1 |
1 |
| 46 | 21262843 | Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. | Proc Natl Acad Sci U S A | 2011 Feb 8 |
5 |
| 47 | 21514278 | The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. | Biochem Biophys Res Commun | 2011 May 6 |
1 |
| 48 | 21600273 | Increasing oxime efficacy by blood-brain barrier modulation. | Toxicol Lett | 2011 Sep 25 |
1 |
| 49 | 21677164 | A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. | J Neurosci | 2011 Jun 15 |
3 |
| 50 | 21692796 | In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. | Epilepsia | 2011 Oct |
1 |